Fulminant myocarditis as an early presentation of SARS-CoV-2.

BMJ Case Rep

Department of Cardiology, County Hospital Hereford, Hereford, Herefordshire, UK.

Published: September 2020

Myocarditis is well known to be caused by viral infections such as Coxsackie virus group B, human herpes virus 6 and parvovirus B19. However, during the current emerging outbreak of SARS-CoV-2, there have been few case reports describing myocarditis as a possible presentation. In our case report we describe, early cardiac manifestations of SARS-CoV-2 in a UK District General Hospital. A 44-year-old Caucasian woman without any comorbidities presented with SARS-CoV-2 related fulminant myocarditis without initial respiratory symptoms. Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility. This was then followed by a second phase of SARS-CoV-2 associated pneumonia and renal failure requiring ventilatory support and haemofiltration. Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490957PMC
http://dx.doi.org/10.1136/bcr-2020-237553DOI Listing

Publication Analysis

Top Keywords

fulminant myocarditis
12
sars-cov-2 fulminant
8
milrinone methylprednisolone
8
sars-cov-2
6
myocarditis early
4
early presentation
4
presentation sars-cov-2
4
myocarditis
4
sars-cov-2 myocarditis
4
myocarditis well
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!